作为HFpEF患者不良结果的预测因子,心房间间隔阻塞是不良结果的预测因子
Jerremy Weerts1,2, Sanne G J Mourmans1, Helena Lopez-Martinez2
1Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands.
ESC heart failure
|December 2, 2024
概括
间阻塞 (IAB) 表明电功能障碍,并预测心力衰竭的不良事件与保存的射出小部分 (HFpEF). 没有IAB的患者对不良结果的风险非常低.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭研究研究
背景情况:
- 心房间隔阻塞 (IAB) 是电心房功能障碍的标志物,与心房动 (AF) 和不良事件的风险增加有关.
- 在心力衰竭中IAB的预后意义与保存的喷射分数 (HFpEF) 并未得到充分确立.
研究的目的:
- 为了确定 HFpEF 患者中 IAB 的患病率.
- 为了调查IAB和AF与HFpEF在门诊和最近入院的环境中的不良事件的关联.
主要方法:
- 在HFpEF患者中分析了基线心电图和病史.
- 患者被分为没有IAB的HFpEF,有IAB或有AF.
- 不良事件包括HF住院,心脏病死亡或33个月的突然死亡.
主要成果:
- 在门诊HFpEF患者中,复合终点的发病率为0% (没有IAB),11% (IAB) 和24% (AF).
- 在最近住院的HFpEF患者中,复合终点的发病率为32% (没有IAB),42% (IAB) 和79% (AF).
- 电动心房功能障碍 (IAB和AF) 的渐进阶段与不良事件的风险显著增加有关.
结论:
- 渐进性电动心房功能障碍 (IAB和AF) 作为HFpEF患者不良结果的预后标志物.
- 没有IAB的门诊HFpEF患者表现出非常低的不良结果风险.
- 需要进一步的研究来确定这些低风险患者是否受益于不那么密集的治疗.
更多相关视频
08:05Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
2.6K
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
1.7K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:28Disturbances in Heart Rhythm
904
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
904